|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||20.90 / 83.95|
These ARK Funds family funds are focused on new opportunities and investment themes.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
You have to be willing to chase if you want to establish new positions.
The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.